```html

Acute Migraine – Comprehensive Medical Guide

Overview

A migraine is a neurovascular headache disorder characterized by recurrent attacks of moderate‑to‑severe throbbing pain, often accompanied by nausea, vomiting, and sensitivity to light or sound. When the attack comes on suddenly, reaches peak intensity within minutes, and lasts less than 72 hours, it is classified as an acute migraine.

Migraine affects about 12 % of the global population (approximately 1 billion people) and is three times more common in women than men. The condition typically begins in adolescence or early adulthood, with a peak prevalence between ages 25‑45, but it can occur at any age, including childhood.

Symptoms

Acute migraine attacks follow a relatively predictable pattern, although the exact presentation can vary from person to person. The International Headache Society (IHS) defines the following core features:

• Pain location: Usually unilateral (one side of the head) but can be bilateral.
• Pain quality: Pulsating or throbbing.
• Intensity: Moderate to severe (often 7‑10/10 on a pain scale).
• Duration: 4–72 hours if untreated.
• Aggravation by routine physical activity (e.g., climbing stairs).
• Associated symptoms (≥1):
• Nausea or vomiting.
• Photophobia (sensitivity to light).
• Phonophobia (sensitivity to sound).
• Osmophobia (sensitivity to odors).
• Aura (optional): Visual disturbances (flashing lights, zig‑zag lines), sensory changes (tingling), or speech difficulties that precede the pain by 5‑60 minutes and usually resolve within an hour.

Red‑flag symptoms that suggest a secondary cause (e.g., bleed, infection) include sudden “worst‑ever” headache, fever, neck stiffness, neurological deficits, or onset after head trauma.

Causes and Risk Factors

Pathophysiology

Exact mechanisms are still being clarified, but current evidence points to a combination of:

• Cortical spreading depression: A wave of neuronal depolarization that triggers aura and activates pain pathways.
• Trigeminovascular system activation: Release of vasoactive peptides (e.g., CGRP, substance P) causing dilation of meningeal vessels and inflammation.
• Genetic predisposition: Mutations in genes such as *CACNA1A*, *ATP1A2*, and *SCN1A* increase susceptibility (particularly in familial hemiplegic migraine).

Risk Factors

• Female sex – estrogen fluctuations (menstrual cycle, pregnancy, menopause) modulate migraine frequency.
• Family history – first‑degree relatives with migraine increase risk 2‑3‑fold.
• Age – onset usually before 35 years.
• Hormonal medications – oral contraceptives, hormone replacement therapy.
• Triggers (see Prevention section): stress, sleep deprivation, certain foods (aged cheese, processed meats), alcohol (especially red wine), caffeine overuse/withdrawal, bright or flickering lights, strong odors, weather changes.
• Comorbid conditions – depression, anxiety, obesity, hypertension, sleep apnea.

Diagnosis

Diagnosis is clinical, based on a detailed headache history and physical examination. The IHS International Classification of Headache Disorders, 3rd edition (ICHD‑3) provides criteria that must be met for an acute migraine diagnosis.

Key Steps

1. History taking: Onset, location, quality, duration, aggravating/relieving factors, associated symptoms, frequency, and aura.
2. Physical & neurological exam: Usually normal between attacks; any focal deficits warrant further work‑up.
3. Red‑flag screening: Sudden onset, age > 50, immunosuppression, cancer, trauma, or signs of increased intracranial pressure.

Diagnostic Tests (when indicated)

• Neuroimaging (MRI with/without contrast) – to rule out structural lesions if red flags are present.
• CT scan – fast assessment for acute hemorrhage or mass effect in emergency settings.
• Blood work – CBC, ESR/CRP if infection or inflammatory disease suspected.
• Lumbar puncture – rare, only if meningitis, subarachnoid hemorrhage, or increased intracranial pressure is in the differential.

Treatment Options

Treatment is divided into abortive (acute) and preventive (prophylactic) strategies. For an acute migraine attack, the goal is rapid pain relief, nausea control, and restoration of function.

Abortive Medications

Drug Class	Examples	Typical Use
Simple analgesics	Acetaminophen, Ibuprofen, Naproxen	Mild‑moderate attacks; take early.
Triptans	Sumatriptan, Zolmitriptan, Rizatriptan, Naratriptan	Moderate‑severe attacks; most effective if taken within 1 hour of onset.
Ergots	Dihydroergotamine (IV, nasal spray), Ergotamine + caffeine	Patients who do not respond to triptans; less commonly used.
CGRP antagonists (Gepants)	Rimegepant, Ubrogepant	Newer agents for patients with contraindications to triptans.
Anti‑nausea agents	Metoclopramide, Prochlorperazine, Ondansetron	Control vomiting & improve oral medication absorption.
Ditans	Lasmiditan	Selective 5‑HT1F agonist; useful when triptans are contraindicated.

Adjunct Non‑Pharmacologic Measures

• Apply a cold pack to the forehead or neck.
• Rest in a dark, quiet room.
• Hydration – 250‑500 mL of water or electrolyte solution.
• Acupressure or relaxation breathing techniques.

Preventive Therapies (for frequent ≥4 attacks/month)

• Beta‑blockers: Propranolol, Metoprolol.
• Antidepressants: Amitriptyline, Venlafaxine.
• Anticonvulsants: Topiramate, Valproate.
• CGRP monoclonal antibodies: Erenumab, Fremanezumab, Galcanezumab (monthly subcutaneous injections).
• Botulinum toxin A: OnabotulinumtoxinA injections for chronic migraine (>15 headache days/month).

Procedural Options (rare, for refractory cases)

• Occipital nerve block or greater occipital nerve stimulation.
• Transcranial magnetic stimulation (single‑pulse TMS) approved for acute treatment.
• Deep brain stimulation (experimental).

Living with Acute Migraine

Day‑to‑Day Management Tips

• Keep a migraine diary: Record triggers, timing of medication, response, and menstrual cycle (if applicable).
• Establish a “migraine kit” with your rescue meds, anti‑nausea tablets, water bottle, and sunglasses.
• Schedule regular meals – skipping meals can precipitate attacks.
• Maintain a consistent sleep schedule: 7‑9 hours per night; avoid >2‑hour variations.
• Exercise regularly (30 min moderate activity most days) – improves stress tolerance and may reduce frequency.
• Limit caffeine to ≤200 mg/day and avoid abrupt withdrawal.
• Use protective eyewear at work if exposed to bright or flickering lights.
• Communicate with employers/teachers: Request accommodations like flexible breaks or reduced screen time.

Prevention

Lifestyle Strategies

• Identify and avoid personal triggers using a diary.
• Adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, fish, and olive oil.
• Stay hydrated (≈2 L water/day).
• Practice stress‑reduction techniques: mindfulness, yoga, progressive muscle relaxation.
• Monitor hormone changes; discuss prophylactic options with a physician if migraines are menstrual‑related.

Pharmacologic Prevention

If you experience ≥4 migraine days per month or acute medications are needed >10 days/month (risk of medication‑overuse headache), discuss preventive therapy with your clinician. Start low and titrate slowly, monitoring for side effects.

Complications

When acute migraine is inadequately treated or ignored, several complications may arise:

• Medication‑overuse headache (MOH): Daily or near‑daily use of analgesics or triptans can paradoxically cause chronic daily headache.
• Chronic migraine: Progression to ≥15 headache days/month for >3 months.
• Functional impairment: Lost work days, reduced academic performance, emotional distress.
• Serious secondary conditions: Although rare, untreated severe headache could mask intracranial hemorrhage, tumor, or infection.
• Psychiatric comorbidities: Higher rates of depression and anxiety, which in turn worsen migraine burden.

When to Seek Emergency Care

References

• Mayo Clinic. Migraine. https://www.mayoclinic.org/diseases‑conditions/migraine/head‑about/
• American Migraine Foundation. “Migraine Statistics.” 2023.
• International Headache Society. ICHD‑3. https://ichd‑3.org/
• National Institute of Neurological Disorders and Stroke (NINDS). “Migraine Information Page.” https://www.ninds.nih.gov/
• World Health Organization. “Headache disorders: a global burden.” WHO Press, 2019.
• Cleveland Clinic. “Migraine Treatment Options.” https://my.clevelandclinic.org/health/diseases/4488-migraine

```